Pulmatrix Q1 net loss widens to $5.0M; cash $47.5M extends runway to Q2 2024

Pulmatrix, Inc.

Net loss of $5.0M ($1.51 per share) vs $4.1M loss in Q1 2021; revenue fell to $1.2M from $1.4M.
Ended Q1 with $47.5M cash; cash runway extended into Q2 2024, through Pulmazole Phase 2b data readout.
Pulmazole Phase 2b on track to start dosing Q1 2023; top-line data expected Q2 2024.
PUR3100 Phase 1 top-line data expected in Q4 2022 from Australian study.
Completed 1-for-20 reverse stock split and regained Nasdaq compliance in March 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.